Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 2/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | THPO | P40225 | 2/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1083381 | 0.98 | MAPT (0.63) | SLC29A1MAPTSCN1ASCN2ASCN3A | |
| SCHEMBL7152725 | 0.83 | KMT2A (0.64) | MAPTCYP3A4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9680396 | 0.82 | SLC29A1 (0.66) | SLC29A1SCN1ASCN2ASCN3ACYP3A4 | |
| Hydrochloric Acid SCHEMBL3054058 | 0.82 | KMT2A (0.63) | MAPTCYP3A4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7956551 | 0.81 | SLC29A1 (0.64) | SLC29A1MAPTSCN1ASCN2ASCN3A | |
| SCHEMBL7406236 | 0.81 | SLC29A1 (0.64) | SLC29A1MAPTSCN1ASCN2ASCN3A | |
| Hypochlorous Acid SCHEMBL3054060 | 0.81 | KMT2A (0.62) | MAPTCYP3A4KMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28743063 | 0.81 | KMT2A (0.62) | MAPTCYP3A4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11219537 | 0.79 | SCN1A (0.69) | SLC29A1SCN1ASCN2ASCN3ACYP3A4 | |
| SCHEMBL8055892 | 0.79 | SCN1A (0.69) | SLC29A1SCN1ASCN2ASCN3ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277510-B1 | Controlled release preparation | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8449911-B2 | Drug composition having active ingredient adhered at high concentration to spherical core | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7790755-B2 | dexlansoprazole FDA Orange book listed patent; capsules with pH dependently soluble polymers such as methyl methacrylate-methacrylic acid copolymers or cellulose esters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790755-B2 | dexlansoprazole FDA Orange book listed patent; capsules with pH dependently soluble polymers such as methyl methacrylate-methacrylic acid copolymers or cellulose esters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| EP-1513527-B1 | PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS | TAKEDA PHARMACEUTICAL (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20060159760-A1 | Drug composition having active ingredient adhered at high concentration to spherical core | AOYAMA & PARTNERS | 2006-07-20 | — | — | US | disclosed |
| EP-1602362-A1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | Takeda Pharmaceutical Company Limited (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-1553929-A2 | CONTROLLED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004035020-A2 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | SLC29A1 3319/4885MAPT 1399/4885SCN1A 4339/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | SLC29A1 3319/4885MAPT 1399/4885SCN1A 4339/4885 |
| US-20060159760-A1 | Drug composition having active ingredient adhered at high concentration to spherical core | SLC18A1, MAST1, ABCG2 | SLC29A1 2959/4885MAPT 14/4885SCN1A 1706/4885 |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | SLC29A1 3319/4885MAPT 1399/4885SCN1A 4339/4885 |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | SLC29A1 3319/4885MAPT 1399/4885SCN1A 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.